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Abstract
Background: Urinary betaine excretion positively correlated with plasma homocysteine in outpatients attending a lipid
disorders clinic (lipid clinic study). We aimed to confirm this in subjects with established vascular disease.
Methods: The correlation between betaine excretion and homocysteine was compared in samples collected from subjects 4
months after hospitalization for an acute coronary episode (ACS study, 415 urine samples) and from 158 sequential patients
visiting a lipid disorders clinic.
Principal findings: In contrast to the lipid clinic study, betaine excretion and plasma homocysteine did not correlate in the
total ACS cohort. Differences between the patient groups included age, non-HDL cholesterol and medication. In ACS
subjects with below median betaine excretion, excretion correlated (using log transformed data) negatively with plasma
homocysteine (r=20.17, p=0.019, n=199), with no correlation in the corresponding subset of the lipid clinic subjects. In
ACS subjects with above median betaine excretion a positive trend (r=+0.10) between betaine excretion and homocysteine
was not significant; the corresponding correlation in lipid clinic subjects was r=+0.42 (p=0.0001). In ACS subjects,
correlations were stronger when plasma non-HDL cholesterol and betaine excretion were above the median, r=+0.20
(p=0.045); in subjects above median non-HDL cholesterol and below median betaine excretion, r=20.26 (p=0.012). ACS
subjects taking diuretics or proton pump inhibitors had stronger correlations, negative with lower betaine excretion and
positive with higher betaine excretion.
Conclusions: Betaine excretion correlates with homocysteine in subjects with elevated blood lipids.
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Introduction
Betaine has central roles in mammalian metabolism both as an
osmolyte and inthestorageandtransfer ofone-carbon units[1,2].It
is obtained from the diet, either directly or by the metabolism of
dietary choline [1]. Disturbances in betaine metabolism have been
linked to various diseases [1,3,4], but most often with vascular
disease. Plasma betaine concentrations are low in patients with the
metabolic syndrome [5] and in patients with lipid disorders [6], and
evidence that betaine plays a role in the metabolic syndrome is
growing [1]. An abnormal excretion of betaine, both high and low
has been associated with diabetes and other diseases [7]. We
previously reported that betaine excretion in subjects with lipid
disorders correlated strongly with plasma homocysteine [6],
especially in male subjects [8]. This implied that betaine loss was
disturbingone-carbon metabolism in the study population, in which
both plasma and urine betaine were major determinants of
homocysteine. There is a plausible mechanism for such a
connection, since betaine-homocysteine methyltransferase is a
major determinant of homocysteine [9,10], and therefore a betaine
deficiency could be expected to cause elevated plasma homocyste-
ine. However, we have not observed this relationship between
betaine excretion and homocysteine in other populations including
an Acute Coronary Syndrome cohort [11], and small studies of hip
fracture patients [12] and stroke patients [13]. Elucidating the
reasons for this difference could provide important information
about the role of betaine in health and disease, and about the
potential of dietary betaine intake for modifying disease risk.
A small sample of ambulant elderly subjects provided evidence
that the positive correlation between urinary betaine and plasma
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lipids [14]. In the present study, we explored this relationship in a
larger acute coronary syndrome cohort, and have compared these
data with data from the lipid disorders clinic cohort. Our aim was
to confirm the previous finding, and to identify factors that would
define populations in which betaine excretion was related to
plasma homocysteine.
Methods
Subjects
All study protocols were approved by the Canterbury Ethics
Committee, and all subjects gave written informed consent.
The ‘‘ACS cohort’’ in this report was the previously described
[11] sub-study using the Acute Coronary Syndrome (ACS) cohort.
Inclusion criteria were as in De Lemos et al [15]. Exclusion
criteria: Severe co-morbidity limiting life expectancy to less than 3
years. For the betaine sub-study fasting plasma samples were
collected on 531 subjects at the four-month post-event follow-up
visit to the clinic. Matching urine samples on 415 of these subjects
were used in the present study.
The lipid clinic cohort has been previously described [6,8].
Subjects (n=158) attending the adult lipid disorders outpatient
clinic at Christchurch Hospital, New Zealand were enrolled into
the study. Subjects with diabetes were excluded.
In both studies fasting plasma and morning urine samples were
collected on all subjects. Blood for homocysteine measurements
was collected on ice. Samples were assayed for high volume
laboratory tests within hours of collection, specimens for
homocysteine, betaine and dimethylglycine assays were frozen at
216uC and assayed within two weeks.
Drug treatments and the diagnosis of diabetes were taken from
clinical records.
Laboratory methods
Betaine and N,N-dimethylglycine were measured in plasma and
urine by high performance liquid chromatography (HPLC) by
separation of their 2-naphthacyl derivatives on Merck Aluspher
alumina columns [16,17] with UV detection at 249 nm. Plasma
homocysteine was measured by fluorescence polarization on an
Abbott IMX Analyzer (Abbott Laboratories USA). Other
biochemical measures in plasma and urine were all made by
standard kit procedures in an International Accreditation New
Zealand accredited laboratory, using an Abbott Aeroset Analyzer
(Abbott Laboratories). Creatinine was measured using the Jaffe ´
reaction, plasma cholesterol was measured by an enzymatic
cholesterol oxidase reaction, triglycerides by enzymatic hydrolysis
of triglycerides, both using Abbott reagents, and HDL cholesterol
was measured by an enzymatic reaction using Roche reagents (La
Roche Ltd, Switzerland).
Drug treatment and clinical diagnoses of diabetes were taken
from the clinical records.
Statistical analysis
Statistical analyses were carried out using SigmaPlot for
Windows version 11.2 (Systat Software Inc), which incorporates
SigmaStat.
In both sets of study data, urine betaine and N,N-dimethylgly-
cine excretions were positively skewed, and in the ACS study
plasma betaine, dimethylglycine and homocysteine concentrations
were also positively skewed. Log-transformed data were normally
distributed. Therefore all data were log transformed prior to
conducting the correlation and regression analyses. Pearson’s
correlation coefficients were used to assess the strength of the
associations between plasma and urine levels. Comparisons
between cohorts and subgroups were undertaken using the non-
parametric Mann-Whitney U tests. Multiple-linear regression
models were used to determine the independent role of a number
of putative predictors of plasma homocysteine. A two-tailed p-
value,0.05 was taken to indicate statistical significance.
For estimating correlations, plasma betaine and N,N-dimethyl-
glycine concentrations were adjusted for gender. In the ACS
cohort, the mean male betaine concentration was 20.5% higher
than the female mean; dimethylglycine was 11.7% higher in
males. In the lipid clinic cohort, male plasma betaine concentra-
tions were 34.4% higher than female; dimethylglycine was 18.6%
higher in males. For adjustment, the raw concentrations for female
subjects were multiplied by the appropriate factor to generate
adjusted results with the same mean and standard deviations for
both genders.
Correlation and regression statistics are reported with the
number of valid data pairs quoted in the results, and with
significance based on these. As a result of missing data these
comparisons are usually based on fewer than the number of
subjects in the ACS study. The significances of differences between
correlation coefficients were evaluated using Fisher r-to-z
transformations.
Results
Differences between cohorts
The lipid clinic cohort (for which diabetes was an exclusion
criterion) was younger with a higher proportion of female subjects
than the ACS cohort (Table 1). The most notable differences
were the median plasma betaine concentrations and the plasma
non-HDL cholesterol concentrations. The ACS cohort was also
more heavily medicated (Table 1) and included subjects with
diabetes. The upper quartile plasma betaine concentration of the
lipid clinic cohort is less than the lower quartile plasma betaine in
the ACS study, and the lower quartile of the non-HDL cholesterol
concentration in the lipid clinic study is above the upper quartile of
the ACS study.
Correlations between betaine, dimethylglycine and
homocysteine
In the ACS population, plasma betaine, dimethylglycine and
homocysteine concentrations approximated a log-normal distri-
bution, so Pearson’s correlation was estimated using log-trans-
formed data. Plasma dimethylglycine concentrations correlated
with both plasma homocysteine and plasma betaine concentra-
tions (Table 2), but neither plasma betaine concentrations nor
urine betaine excretion correlated with plasma homocysteine. The
urinary excretion of dimethylglycine correlated with plasma
dimethylglycine, but there was no correlation between urine and
plasma betaine. When the genders were examined separately, the
only significant difference was a stronger (p=0.02) positive
correlation between plasma dimethylglycine and homocysteine
in females.
For comparison, the data from the lipid clinic cohort was re-
analyzed in exactly the same way, comparing log(homocysteine)
with log(urinary excretions), despite a more normal distribution of
betaine and homocysteine concentrations. The notable difference
compared with the ACS cohort was that the urine betaine and
dimethylglycine excretions correlated with plasma homocysteine.
This correlation between log(urine betaine excretion) and
log(plasma homocysteine) was stronger in the male subjects
(r=+0.51, p,0.0001) than in the female subjects (r=+0.23,
p=0.039); difference in correlations, p=0.048.
Urine Betaine and Plasma Homocysteine
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One difference between the cohorts was the inclusion of subjects
with diabetes in the ACS cohort. Excluding subjects with diabetes
did not change the differences between the cohorts shown in
Table 1, and did not significantly change the correlations shown in
Table 2. No significant correlations between betaine excretion
and plasma homocysteine were detected in ACS subjects with
(n=67) or without (n=321) diabetes, even though high excretions
of both betaine and dimethylglycine were more common in
subjects with diabetes (Figure 1).
Different patterns associated with high and low betaine
excretion
We have found that both high and low betaine excretion may
be associated with disease [7]. Therefore, the above median
betaine excretion and below median excretion subsets of the
populations were analysed separately. In the low betaine excretion
subsample of the ACS cohort (Table 3), there was a weak but
significant negative correlation between betaine excretion and
homocysteine; in the high betaine excretion subsample there was a
non-significant trend for a positive association. Excluding subjects
with diabetes had no effect on the below median excretion
subgroup; the positive trend in the high excretion subgroup was
strengthened by excluding subjects with diabetes (diabetes
excluded, r=+0.16, p=0.054). The corresponding results in the
lipid clinic cohort showed a strong association between betaine
excretion and plasma homocysteine in the above-median betaine
excretion subjects (r=+0.42, n=79, p=0.0001) but no correlation
was detected in the below median excretion subjects (r=20.07,
n=79, p=0.55).
Differences between subgroups based on plasma lipids,
age and plasma betaine
Since the largest differences between the ACS cohort and the
lipid clinic cohort were in non-HDL cholesterol, age, and plasma
betaine the populations were divided on the basis of these factors
into those subjects above the median and those below the median
for each factor (Table 4). Plasma non-HDL cholesterol was most
Table 1. Comparison of study populations.
ACS study Lipid clinic study
Males Females Males Females
Number 297 118 77 81
Age (median, total range) 66 (55–93) 72 (51–91)
{ 52 (43–59)
*** 56 (48–63)
{***
With diabetes (%) 16% 20% 0 0
BMI (median, IQ range) 26.3 (24.5–29.4) 27.4 (22.9–31.7) 28.4
** (25.7–31.8) 27.2 (24.3–31.0)
Pl betaine mmol/L 42.1 (34.4–54.7) 38.0(30.5–44.1)
{{{ 24.9 (19.2–31.9)
*** 20.0 (15.0–25.6)
{{{***
Pl dimethylglycine mmol/L 3.7 (2.6–4.9) 3.2 (1.9–4.7)
{ 2.1 (1.5–2.7)
*** 1.8 (1.4–2.2)
***
Pl total homocysteine mmol/L 12.5 (10.4–15.8) 12.3 (10.1–15.6) 9.8 (8.6–12.2)
*** 9.6 (7.7–12.2)
***
Pl creatinine mmol/L 100 (89–110) 80 (71–100)
{{{ 80 (70–90)
*** 70 (60–80)
***
Pl urea mmol/L 6.5 (5.4–8.2) 6.4 (4.9–8.0) – –
Pl triglycerides mmol/L 1.50 (1.05–2.08) 1.47 (1.01–2.03) 2.25 (1.60–3.30)
*** 1.82 (1.27–2.35)
{{**
Pl HDL cholesterol mmol/L 1.07 (0.89–1.25) 1.25 (1.06–1.50)
{{{ 1.01 (0.87–1.30) 1.29 (1.10–1.55)
{{{
Pl non-HDL cholesterol mmol/L 3.0 (2.5–3.7) 3.3 (2.6–4.3)
{ 5.8 (5.1–6.6)
*** 5.5 (4.8–6.3)
***
Betaine excretion 9.4 (6.0–18.1) 8.2 (4.4–17.7) 7.4 (5.0–13.9)
* 8.1 (4.8–15.6)
Dimethylglycine excretion 2.9 (1.5–5.8) 2.4 (1.4–4.3) 3.8 (1.7–7.1) 3.2 (1.8–6.6)
*
% on statins 89 81 17 21
% on ACE inhibitors 57 49 17 9
% on angiotensin II antagonists 8 10 0 0
% on diuretics 26 37 6 6
% on aspirin 94 96 12 9
% on clopidogrel 41 30 0 0
% on beta-blockers 88 81 9 9
% on calcium channel blockers 29 41 3 4
% on proton pump inhibitors 39 42 8 5
% current smoker 6 10 – –
The ACS study data are on subjects who supplied urine samples. Median values with interquartile ranges unless otherwise stated. cr: creatinine. DMG: N,N-
dimethylglycine. IQ: interquartile. Plasma (Pl) betaine, dimethylglycine and homocysteine in mmol/L; triglycerides and cholesterol fractions in mmol/L; excretions in
mmol/mole creatinine. Significance (based on rank-sum test): difference between study populations,
*p,0.05;
**p,0.01;
***p,0.001; difference between genders,
{p,0.05;
{{p,0.01;
{{{p,0.001.
doi:10.1371/journal.pone.0032460.t001
Urine Betaine and Plasma Homocysteine
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excretion and plasma homocysteine. In subjects with above median
non-HDL cholesterol and above median betaine excretion there was
a trend towards a positive correlation between betaine excretion and
plasma homocysteine, whereas in the subjects with above median
non-HDL cholesterol and below median betaine excretion there was
a trend towardsa negative correlationbetweenbetaine excretionand
plasma homocysteine. These trends were not apparent in subjects
with below median non-HDL cholesterol. The robustness of these
trends was tested by estimating the correlations in the highest tertile
and highestquartileof plasma non-HDL cholesterol.In subjectswith
above median betaine excretion, the Pearson’s correlations (log-
transformed homocysteine and urine excretion data) inthe top tertile
were r=+0.26 (p=0.028) and in the top quartile r=+0.28
(p=0.049). In subjects with below median betaine excretion, the
correlations in the top tertile were r=20.34 (p=0.005) and in the
top quartile r=20.35 (p=0.015). The correlations remained when
subjects with diabetes were excluded; above median for both betaine
excretion and non-HDL cholesterol, r=+0.25 (p=0.032, n=73)
and below median for betaine excretion but above median for non-
HDL cholesterol, r=20.24 (p=0.025, n=87).
Non-HDL cholesterol consistently did not correlate with
homocysteine, neither in univariate correlations, nor when multiple
regression models were estimated in these subgroups. In models
with log(plasma homocysteine) as the dependent variable, and the
independent variables plasma (gender adjusted) and urine betaine
Table 2. Correlations between betaine, dimethylglycine and homocysteine in the two populations.
Plasma dimethylglycine
(mmol/L)
Plasma homocysteine
(mmol/L)
Betaine excretion
(mmol/mole)
Dimethylglycine
excretion (mmol/mole)
A. ACS study
Plasma betaine (mmol/L)
r= +0.26 20.06 +0.027 20.016
p= ,0.00001 0.15 0.59 0.75
n= 523 510 393 393
Plasma dimethylglycine (mmol/L)
r= +0.25 +0.05 +0.16
p= ,0.00001 0.33 0.0013
n= 510 393 393
Plasma homocysteine (mmol/L)
r= +0.019 +0.017
p= 0.70 0.74
n= 402 402
Betaine excretion (mmol/mole)
r= +0.54
p= ,0.00001
n= 415
B. Lipid clinic study
Plasma betaine (mmol/L)
r= +0.25 20.02 +0.08 20.10
p= 0.0017 0.77 0.30 0.22
n= 158 158 158 158
Plasma dimethylglycine (mmol/L)
r= 0.0076 +0.03 +0.03
p= +0.21 0.69 0.67
n= 158 158 158
Plasma homocysteine (mmol/L)
r= +0.35 +0.29
p= ,0.00001 0.0002
n= 158 158
Betaine excretion (mmol/mole)
r= +0.59
p= ,0.00001
n= 158
Pearson’s correlation coefficients calculated using log-transformed data. Plasma betaine and dimethylglycine concentrations corrected for gender difference. Excretions
measured as mmole/mole creatinine. Significant correlations in bold.
doi:10.1371/journal.pone.0032460.t002
Urine Betaine and Plasma Homocysteine
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independent variables had variance inflation factors ,1.2, with age
appearing as the strongest predictor of homocysteine.
The lipid clinic study data was also divided into groups based on
the medians of betaine excretion and plasma non-HDL choles-
terol. In the above median betaine excretion and above median
non-HDL cholesterol group (n=39), the Pearson’s correlation
coefficient between plasma homocysteine and urine betaine
excretion (both log-transformed) was r=+0.52 (p=0.00066)
whereas in the below median betaine excretion and above median
non-HDL cholesterol group (n=40) the corresponding correlation
was not significant, r=+0.13 (p=0.42).
Drug therapy, betaine and homocysteine
In the ACS cohort, plasma betaine concentrations and betaine
excretions were significantly different in subjects taking some
medications (Table 5). As well as the previously reported [11]
differences between subjects taking lipid lowering drugs, plasma
betaine was also higher in subjects taking beta-blockers and lower
in subjects taking angiotensin II antagonists. Apart from fibrates,
no other drug treatment was associated with a significant
difference in betaine excretion.
Because medication was one of the main differences between
the ACS cohort and the lipid clinic cohort (Table 1), correlations
were estimated between plasma homocysteine, plasma betaine and
betaine excretion, and plasma dimethylglycine and dimethylgly-
cine excretion, in the above and below median betaine excretion
groups of the high plasma lipid subgroups of the ACS cohort that
were being treated with different medications. These were
compared with subgroups not being treated (Table 6). There
were too few subjects being treated in the lipid clinic cohort for a
comparable analysis. To enhance comparability with the lipid
disorders clinic cohort, the correlations are reported with subjects
with diabetes excluded, but in all cases there were only minor and
insignificant differences when these subjects were included. The
trends for a positive correlation between high betaine excretion
and homocysteine, and for a negative correlation between low
betaine excretion and homocysteine, were robustly reproduced in
different subgroups. The positive correlation between plasma
homocysteine and betaine excretion, in subjects with above
median betaine excretion, increased in subjects not being treated
with ACE inhibitors or clopidogrel, and in those not receiving
proton pump inhibitors. The negative correlation between low
betaine excretion and homocysteine was greater insubjects treated
with diuretics (p=0.020) or proton pump inhibitors (p=0.044).
There were too few subjects not taking aspirin for a similar
comparison (Table 1), though omitting these subjects had a
negligible effect on the results. A highly significant effect was seen
with subjects treated with angiotensin II receptor antagonists;
there were too few of these to analyse the data in the same way,
but in the group of all subjects without diabetes being treated with
these drugs (n=24) the correlation between log(urine betaine
excretion) and log(plasma homocysteine), Pearson’s r=+0.77
(p=0.00001); if subjects with diabetes are included (n=34),
r=+0.44 (p=0.009).
To a lesser extent, relationships other than that between
homocysteine and betaine excretion were changed in subgroups
treated with some drugs (Table 6). In six sub-groups there was a
significant (p,0.05) negative correlation between plasma betaine
and homocysteine. The strongest correlation was in subjects
treated with calcium channel blockers and above the median for
both betaine excretion and for plasma non-HDL cholesterol,
r=20.51 (n=34, p=0.002).
Discussion
In our previous study of subjects attending a lipid disorder
clinic, we found a strong association between plasma homocyste-
ine and betaine excretion [6], and the urinary betaine excretion
was the strongest determinant of plasma homocysteine in the male
subjects [8]. We were therefore surprised when similar associations
were not seen in several subsequent studies, some briefly described
elsewhere [13,14] and some unpublished [12,13]. We have shown
here that our previous results [6,8] were serendipitous conse-
quences of the population we sampled. One cohort that did not
show the expected correlation was the ACS study group, who were
stabilized subjects recruited at a clinic visit approximately four
months after hospital admission following a cardiovascular event.
These differed from the lipid disorders clinic subjects in that
almost all were receiving standard cardiovascular medications
including lipid lowering agents. Few of them had elevated plasma
lipids when studied, whereas in contrast, the subjects recruited
from the lipid clinic required specialist outpatient management for
disordered lipid profiles. The differences were large; the bottom
quartile of non-HDL cholesterol in the lipid clinic subjects was
above the top quartile in the ACS cohort. We found a positive
Figure 1. Differences in subjects with diabetes. ACS study
subjects with (n=90 plasma, 68 urine) and without (n=425 plasma, 331
urine) diabetes; box shows median and interquartile ranges. Only the
urinary excretions are significantly different (rank sum test), with
excretions higher in diabetes, p,0.001 for betaine, p=0.001 for
dimethylglycine (DMG).
doi:10.1371/journal.pone.0032460.g001
Urine Betaine and Plasma Homocysteine
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homocysteine in sub-groups of the ACS cohort with elevated
plasma lipids, with non-HDL cholesterol a strong marker of this
(with the correlation increasing with increasing non-HDL
cholesterol). In addition, in the total ACS population, there was
a confounding trend for low betaine excretion to negatively
correlate with plasma homocysteine; this trend was weak or absent
in the lipid disorders cohort, and was stronger in the subsets of
ACS subjects treated with drugs such as diuretics and proton
pump inhibitors that were more commonly prescribed to ACS
subjects. The median plasma betaine concentrations in both sexes
of the ACS population were close to normal [1] and were much
higher than those in the lipid disorders cohort. Plasma betaine is
not independent of plasma lipids and an inverse relationship that
has been previously described [5] was present in the ACS
population in this study [11]. The other major difference between
the two study populations is age, which is an independent
determinant of plasma homocysteine and does not explain the
difference; in contrast, although the non-HDL cholesterol
concentration efficiently defines sub-groups in which betaine
excretion determines plasma homocysteine, the lipid concentra-
tion itself did not correlate with plasma homocysteine.
When we examined the cohort of subjects without diabetes who
were attending a lipid disorders clinic, we expected that this group
would have a high proportion of subjects with pre-diabetic
conditions, and we found in this group that betaine (both plasma
concentrations and urinary excretion) was a major determinant of
plasma homocysteine concentrations [6], and in male subjects the
Table 3. Correlations in ACS subjects split on median betaine excretion.
Plasma dimethylglycine
(mmol/L)
Plasma homocysteine
(mmol/L)
Betaine excretion
(mmol/mole)
Dimethylglycine
excretion (mmol/mole)
A. Above median betaine excretion
Plasma betaine (mmol/L)
r= +0.23 20.07 20.05 20.015
p= 0.0015 0.36 0.50 0.84
n= 194 193 194 194
Plasma dimethylglycine (mmol/L)
r= +0.23 20.03 +0.27
p= 0.0016 0.72 0.0001
n= 193 194 194
Plasma homocysteine (mmol/L)
r= +0.10 +0.07
p= 0.14 0.29
n= 194 194
Betaine excretion (mmol/mole)
r= +0.39
p= ,0.00001
n= 208
B. Below median betaine excretion
Plasma betaine (mmol/L)
r= +0.23 20.012 +0.015 20.07
p= 0.001 0.87 0.84 0.33
n= 200 192 200 200
Plasma dimethylglycine (mmol/L)
r= +0.24 20.12 +0.024
p= 0.0009 0.096 0.74
n= 192 200 200
Plasma homocysteine (mmol/L)
r= 20.17 20.056
p= 0.019 0.44
n= 199 199
Betaine excretion (mmol/mole)
r= +0.23
p= 0.0007
n= 208
Pearson’s correlation coefficients calculated using log-transformed data. Plasma betaine and dimethylglycine concentrations corrected for gender difference. Excretions
measured as mmole/mole creatinine. Significant correlations in bold.
doi:10.1371/journal.pone.0032460.t003
Urine Betaine and Plasma Homocysteine
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homocysteine, stronger than folate [8]. In this mainly folate-
replete population we concluded that homocysteine was a marker
of betaine deficiency, and found that betaine loss appears to be
associated with vascular risk [6]. Homocysteine is a well-known
risk factor for cardiovascular disease [18–20]. However, studies in
which folate supplementation decreased the mean plasma total
homocysteine concentrations have not shown a corresponding
decrease in subsequent vascular events [21–23]. There has been
considerable recent discussion of this paradox and a number of
suggested resolutions put forward, which is not surprising given the
strong association between homocysteine and both cardiovascular
Table 4. Effects of plasma lipid, plasma betaine and age on correlations.
Above median betaine excretion Below median betaine excretion
A. Correlations between plasma homocysteine and urine betaine excretion
Above median non-HDL-cholesterol +0.20 (0.045) 20.26 (0.012)
Below median non-HDL-cholesterol +0.01 (0.96) 20.09 (0.38)
Above median age +0.11 (0.29) 20.23 (0.023)
Below median age +0.08 (0.44) 20.04 (0.69)
Above median plasma betaine +0.11 (0.28) 20.24 (0.018)
Below median plasma betaine +0.01 (0.90) 20.05 (0.60)
B. Correlations between plasma homocysteine and plasma betaine
Above median non-HDL-cholesterol 20.26 (0.011) 20.04 (0.72)
Below median non-HDL-cholesterol +0.06 (0.57) 20.01 (0.96)
Above median age 20.19 (0.062) 20.10 (0.34)
Below median age 20.01 (0.93) 20.04 (0.68)
Above median plasma betaine +0.14 (0.18) +0.08 (0.41)
Below median plasma betaine 20.26 (0.010) 20.02 (0.87)
C. Correlations between plasma betaine and betaine excretion
Above median non-HDL-cholesterol 20.21 (0.044) +0.09 (0.37)
Below median non-HDL-cholesterol 20.04 (0.72) +0.03 (0.74)
Above median age 20.08 (0.45) +0.00 (1.00)
Below median age +0.03 (0.76) +0.01 (0.93)
Above median plasma betaine +0.20 (0.053) +0.23 (0.023)
Below median plasma betaine 20.14 (0.16) 20.09 (0.35)
Values are Pearson correlation coefficients between log-transformed variables, with significance (p) in parentheses after correlations. Significant correlations (p,0.05) in
bold. Gender corrected plasma betaine. Urine betaine excretion measured as mmol betaine/mole creatinine. n=101 (97 for plasma betaine).
doi:10.1371/journal.pone.0032460.t004
Table 5. Effect of drugs on plasma betaine and betaine excretion.
Not taking drug Taking drug
Drug category n pl betaine n betaine excretion n pl betaine n betaine excretion
Statins 68 40.2 52 7.6 436 45.9** 349 9.0
Fibrates 493 45.2 392 8.8 12 33.0** 10 99.8***
Diuretics 359 45.2 282 9.2 144 44.1 116 8.1
Beta blockers 78 39.8 56 8.6 426 46.1** 343 9.0
ACE inhibitors 236 45.0 181 9.1 268 45.1 218 8.8
Angiotensin II antagonists 460 45.3 362 8.8 40 42.0* 34 10.7
Clopidogrel 308 45.3 248 8.7 196 44.7 151 9.1
Calcium channel blockers 344 45.3 270 8.5 160 43.3 129 9.8
Proton pump inhibitors 298 43.7 242 8.5 207 46.5 158 9.7
Current smokers 474 45.3 372 8.8 31 37.6 28 12.1
*p,0.05;
**p,0.01;
***p,0.001 compared with subjects not taking the medication.
Median plasma betaine (corrected for gender): mmol/L; betaine excretion: mmol urine betaine/mole creatinine.
doi:10.1371/journal.pone.0032460.t005
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that betaine may be the major determinant of plasma homocys-
teine [1,26] which is largely controlled by the liver enzyme
betaine-homocysteine methyltransferase [9,10], and most discus-
sion is focussed on the role of folate and vitamin B12 mediated
homocysteine lowering. There is now a growing awareness of
importance of betaine in human health [1–4]. It has dual roles as a
key osmolyte and as a source of methyl groups, and tissue
concentrations are typically an order of magnitude higher than
circulating blood concentrations [27]. More than 20% of patients
with diabetes mellitus excrete abnormal amounts of betaine
[28,29]. Since betaine is normally metabolized, and this
metabolism inevitably involves the conversion of homocysteine
to methionine [1], it seemed plausible that betaine loss in the urine
could be both a major determinant of plasma homocysteine
concentrations and be itself pathogenic, and our initial observation
supported this model.
Here we ask why this association between betaine excretion and
homocysteine was not subsequently observed in the ACS study.
This population, and the lipid disorders clinic cohort, were quite
different and neither is typical of the general population. The
contrast in control of homocysteine between the cohorts is most
strongly associated with the large difference in the plasma lipid
profiles of the two populations, and another factor is the difference
in the degree of medication of the subjects. The correlation
between urine betaine excretion and plasma homocysteine
increases in subsets of the present study with higher lipids, but
the number of subjects becomes too small to detect significant
correlations at lipid concentrations well below those in the earlier
study. A confounding factor is the presence of subjects with
abnormally [1] low betaine excretions, as seen in previous studies
[7]: these also appear to be high risk subjects (unpublished data).
Plasma non-HDL cholesterol appears to be a marker of subjects in
whom betaine excretion is related to plasma homocysteine, but
itself is not statistically a determinant of homocysteine. These
results confirm observations made in a smaller study of ambulant
elderly subjects [14]. It is possible that drugs affect betaine and
homocysteine metabolism, but the differences we observed may
reflect differences between the sub-populations that are prescribed
these drugs; the cross-sectional design means that we cannot
distinguish these alternatives, but both are plausible. In the case of
fibrates it is more likely to be an effect of the drug [11,13], and the
same might be true of the angiotensin II antagonists reported here,
but in many cases it is likely that the results reflect the selection of
patients who are treated with that drug. The correlations seen with
low betaine excretions is obviously associated with subjects being
treated with diuretics or proton pump inhibitors, but it does not
necessarily follow that the drug treatment is responsible for the
effect, and since most subjects are on multiple drugs, the effects
suggested by Table 6 are not independent. In the metabolic
syndrome where high blood pressure is common, subjects are
likely to be treated with one or more of the drugs listed in tables 5
and 6. Subjects with the metabolic syndrome are also likely to have
elevated lipids, and we have previously suggested that these are
subjects who are likely to become betaine deficient [1]. Age itself
may not be a critical factor, but further investigation would be
justified into the diseases associated with age, and the effects of
medication used to treat these. We acknowledge that in our
analyses we have made ad-hoc multiple comparisons within
subgroups, and therefore type I errors are not excluded. However,
the consistency of the patterns of correlations suggests robustness
in the results, but a cautious interpretation is required.
In conclusion, the results of the two studies can be reconciled,
but the apparent contradictions are a warning about generaliza-
tions based on a selected patient population. The reconciliation
confirms the association between betaine and lipid metabolism,
and is consistent with a role for betaine in the metabolic syndrome.
These cross-sectional studies suggest a number of hypotheses to be
tested. The results are consistent with our previous suggestions [1]
that betaine plays an important role in the metabolic syndrome,
and this could be tested by longitudinal studies of supplementa-
tion. The cross-sectional results suggest that betaine deficiency is
most apparent in subjects with elevated plasma lipids, and the
hypothesis that there is a causal connection needs to be tested; it
Table 6. Dependancy of correlations on medication.
Correlations between plasma homocysteine and betaine excretion in: Above median betaine excretion Below median betaine excretion
nr p nr p
Subset based on drug treatment:
All subjects without diabetes 73 +0.25 0.032 87 20.24 0.025
No diuretics 52 +0.21 0.13 61 +0.12 0.36
With diuretics 17 +0.11 0.67 26 20.42 0.033
No beta blocker 7 +0.57 0.18 14 +0.12 0.67
With beta blocker 65 +0.26 0.035 73 20.30 0.010
No ACE inhibitor 38 +0.13 0.42 36 20.36 0.036
With ACE inhibitor 34 +0.43 0.011 51 20.15 0.30
No clopidogrel 43 +0.11 0.49 58 20.15 0.26
With clopidogrel 29 +0.46 0.012 29 20.37 0.050
No calcium channel blocker 46 +0.10 0.52 61 20.19 0.14
With calcium channel blocker 26 +0.39 0.051 26 20.21 0.31
No proton pump inhibitor 45 +0.32 0.032 52 +0.01 0.95
With proton pump inhibitor 28 +0.17 0.38 35 20.42 0.011
All data on subjects with above median plasma non-HDL-cholesterol and with subjects with diabetes excluded. Pearson’s correlation coefficients between log (plasma
tHcy) and log(urine betaine/creatinine). Bold significant (p,0.05).
doi:10.1371/journal.pone.0032460.t006
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PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e32460cannot be excluded that it is the elevated lipid that affects betaine,
since in rats a high lipid diet appears to cause an elevation in
betaine excretion [30]. As for mechanisms, the osmolyte role of
betaine needs to be considered as well as its role as a methyl donor,
and this is also consistent with the possibility that betaine
metabolism is affected by drugs that modify the renin-angiotensin
system. Studies to identify such connections may suggest improved
therapeutic strategies that could benefit those subjects with the
metabolic syndrome who have elevated lipids and increased
vascular risk.
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